Douglas Klaiber

Douglas Klaiber is an accomplished executive with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as the Chief Executive Officer of Q-VANT Biosciences since January 2022, Klaiber leads efforts to address supply chain challenges for QS-21 and Quillaja-based saponin adjuvants, utilizing next-generation technology to significantly increase production capabilities. Since April 2019, Klaiber has also held the CEO position at Urobiome Therapeutics, focusing on the development of innovative therapies for urinary microbiome-related diseases. Prior roles include CEO at Naturex-DBS LLC and Decas Botanical Synergies, as well as Sr. Director of Marketing at Taqua Systems. Klaiber holds a B.S. in Mechanical Engineering from Penn State University and an MBA from the University of Pennsylvania (Wharton).